UNSPSC 51331702: Picobenzide

This classification denotes an antipsychotic agent with the molecular formula C15H16N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C46317G8F0, chemically known as 3,5-dimethyl-n-pyridin-4-ylmethyl-benzamide but generally known as picobenzide, which bears US NIH Compound Identifier 40146. European Medicines Agency schedules Picobenzide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09814MIG.

UNSPSC 51331702 Picobenzide, a Commodity code, nominally refers to a specific pharmaceutical ingredient, but state and local procurement activity under this code does not reflect targeted purchases of picobenzide itself. Instead, recent solicitations tagged with this code cover broader pharmaceutical procurement — generic multi-source drugs, over-the-counter products, naloxone and drug deactivation systems, and pharmacy benefit program administration — suggesting either misclassification in posting systems or use of the code as a catch-all for pharmaceutical commodity purchasing. State and local issuing bodies pursuing pharmaceutical procurement through this code include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, serving Minnesota, Oregon, and participating jurisdictions). The scope spans bulk pharmaceutical supply agreements, drug deactivation system procurement, and direct-to-manufacturer prescription program administration.

Recent activity clusters in Florida and the upper Midwest. Seminole County posted an IFB (IFB60459723LAS, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the contract includes a two-year initial term with one-year renewal option and potential FEMA funding. The Texas HHS Commission issued an RFI (HHS0017013, response deadline April 3, 2026) to gather vendor capabilities for direct-to-manufacturer prescription contracting outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance released an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be distributed through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson), with awards effective July 1, 2026 and evaluation weighted 75 percent on price competitiveness. Vendors must demonstrate cGMP certification, Drug Supply Chain Security Act compliance, and contractual relationships with at least two authorized wholesalers.